Brief: Enanta Pharmaceuticals Announces Sale Of A Portion Of Global Royalties On Mavyret® (U.S.)/Maviret® (Ex-U.S.) (Glecaprevir/Pibrentasvir) To Omers Life Sciences For $200 Million
25/04/2023 13:56
April 25 (Reuters) - Enanta Pharmaceuticals Inc
ENTA.O :
* ENANTA PHARMACEUTICALS ANNOUNCES SALE OF A PORTION OF
GLOBAL
ROYALTIES ON MAVYRET® (U.S.)/MAVIRET® (EX-U.S.)
(GLECAPREVIR/PIBRENTASVIR) TO OMERS LIFE SCIENCES FOR $200
MILLION
* ENANTA PHARMACEUTICALS INC - SALE PROCEEDS TO FUND
CONTINUING
CLINICAL DEVELOPMENT ACROSS VIROLOGY PIPELINE
* ENANTA PHARMACEUTICALS INC- PURCHASE PRICE PAID TO ENANTA
FOR
DEAL WAS $200 MILLION
Source text for Eikon: ID:nBw2mQlZYa
Further company coverage: ENTA.O
((Reutersbriefs@thomsonreuters.com;))
Recent news on Enanta Pharmaceuticals
See all newsEnanta Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Enanta Pharmaceuticals Q3 revenue misses estimates, hurt by lower royalties
Enanta Pharmaceuticals Inc expected to post a loss of 51 cents a share - Earnings Preview
Enanta Pharma Q2 loss narrows on higher AbbVie royalties, lower costs
Enanta Pharmaceuticals Q1 revenue beats estimates